Home
/
Protagonist Therapeutics, Inc
/
Financials
/
Quarterly
Protagonist Therapeutics, Inc — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Protagonist Therapeutics, Inc filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$8.78M
Nov 7, 2017
Q3
2017
Sep 30, 2016
$0
Nov 7, 2017
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($39.34M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($34.77M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($11.66M)
May 6, 2025
Q3
2025
Sep 30, 2024
($33.21M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($30.62M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
$207.34M
May 6, 2025
Q3
2024
Sep 30, 2023
($34.11M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($38.46M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($33.73M)
May 7, 2024
Q3
2023
Sep 30, 2022
($31.23M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($41.04M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($20.93M)
May 4, 2023
Q3
2022
Sep 30, 2021
($33.80M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($30.84M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($24.00M)
May 5, 2022
Q3
2021
Sep 30, 2020
($7.76M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($19.42M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($20.08M)
May 4, 2021
Q3
2020
Sep 30, 2019
($16.41M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($29.17M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($46.42M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($42.04M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($19.31M)
May 6, 2025
Q3
2025
Sep 30, 2024
($41.45M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($38.79M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
$206.31M
May 6, 2025
Q3
2024
Sep 30, 2023
($38.33M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($42.35M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($36.02M)
May 7, 2024
Q3
2023
Sep 30, 2022
($32.30M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($41.44M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($21.11M)
May 4, 2023
Q3
2022
Sep 30, 2021
($33.93M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($30.88M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($24.02M)
May 5, 2022
Q3
2021
Sep 30, 2020
($7.77M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($18.22M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($19.70M)
May 4, 2021
Q3
2020
Sep 30, 2019
($17.17M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($31.41M)
Aug 6, 2020